Navigation Links
DOR BioPharma Announces Publication of orBec(R) Clinical Pulmonary Data in Bone Marrow Transplantation
Date:6/29/2009

a Phase 1 clinical trial in normal volunteers.

For further information regarding DOR BioPharma, Inc., please visit the Company's website at www.dorbiopharma.com.

This press release contains forward-looking statements that reflect DOR BioPharma, Inc.'s current expectations about its future results, performance, prospects and opportunities. Statements that are not historical facts, such as "anticipates," "believes," "intends," or similar expressions, are forward-looking statements. These statements are subject to a number of risks, uncertainties and other factors that could cause actual events or results in future periods to differ materially from what is expressed in, or implied by, these statements. DOR cannot assure you that it will be able to successfully develop or commercialize products based on its technology, including orBec(R), particularly in light of the significant uncertainty inherent in developing vaccines against bioterror threats, manufacturing and conducting preclinical and clinical trials of vaccines, and obtaining regulatory approvals, that its cash expenditures will not exceed projected levels, that product development and commercialization efforts will not be reduced or discontinued due to difficulties or delays in clinical trials or due to lack of progress or positive results from research and development efforts, that it will be able to successfully obtain any further grants and awards, maintain its existing grants which are subject to performance, enter into any biodefense procurement contracts with the US Government or other countries, that the US Congress may not pass any legislation that would provide additional funding for the Project BioShield program, that it will be able to patent, register or protect its technology from challenge and products from competition or maintain or expand its license agreements with its current licensors, or that its b
'/>"/>

SOURCE DOR BioPharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
2. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
3. PDL BioPharma Announces Internal CEO Investigation Found No Credible Evidence of Improper Personal Conduct or Breach of Fiduciary Duty
4. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
5. PDL BioPharma Announces Significant Strategic and Portfolio Changes to Focus on Antibody Discovery and Development
6. XTL Biopharmaceuticals Announces Presentation of Novel Pre-Clinical Inhibitors of Hepatitis C at an Upcoming International Scientific Conference
7. XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain
8. Nabi Biopharmaceuticals Announces Sale of Nabi Biologics to Biotest AG
9. Keryx Biopharmaceuticals to Present at Bank of America Investment Conference
10. Morria Biopharmaceuticals Plc Announces Appointment of Dr. Rosemary Mazanet as Interim Chief Executive Officer
11. Keryx Biopharmaceuticals, Inc. Announces Appointment of Michael P. Tarnok to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... Kjell Lindgren , who is making final preparations for ... International Space Station , will be available for live ... 7. Lindgren will participate from the Gagarin Cosmonaut ... The interviews will be preceded at 7:30 a.m. by a ... To schedule an interview, media must contact Stephanie Stoll ...
(Date:6/30/2015)... NEW YORK , June 30, 2015  Today, Americord ... the U.S., announced Andrew Horne , a partner at ... Advisory Board. Logo - http://photos.prnewswire.com/prnh/20150630/226958LOGO   ... appointment to Americord,s Advisory Board," says Martin Smithmyer , ... experience in his legal career that will assist Americord,s growth ...
(Date:6/30/2015)... Kent, WA (PRWEB) , ... June 30, 2015 ... ... offers a hydrophilic filter that does not sacrifice selectivity to achieve faster flow ... construction combines extremely fine pores with significant open space to allow easy liquid ...
(Date:6/30/2015)... ... June 30, 2015 , ... The maximum number of shares ... outstanding common shares (including shares of unvested restricted stock). On June 29, 2015, the ... price of Cryo-Cell’s shares reported on the OTCBB was $2.29 per share. , The ...
Breaking Biology Technology:NASA Astronaut Preps for First Space Station Mission, Available for Media Interviews 2Americord Registry Announces Andrew Horne as Advisory Board Member 2New Nanofiber Membrane Provides Fast, Efficient Filtration 2Cryo-Cell Commences Tender Offer to Purchase its Common Stock, Up to 750,000 Shares at $3.25 per Share 2Cryo-Cell Commences Tender Offer to Purchase its Common Stock, Up to 750,000 Shares at $3.25 per Share 3
... to testing for sleep-related illnesses , , SAN ... of in-home sleep testing and Continuous Positive Airway Pressure ... of the nation,s largest healthcare benefit providers. As a ... able to serve more patients with sleep-related illnesses such ...
... June 16 Strativa Pharmaceuticals, the proprietary products division ... Inc. (NYSE: PRX ), today announced that ... Drug Application (NDA) to the Food and Drug Administration ... buccal tablets, as planned. If approved, Strativa could ...
... , , Harness the Dual Benefits of Freshly ... CHICAGO, June 16 In today,s competitive environment and economic ... a promising new drug compound or chemical entity cannot be ... to do more with less, and productivity and cost savings ...
Cached Biology Technology:SleepQuest Signs National Contract With Aetna 2Strativa's Development Partner, BioAlliance Pharma, Submits Loramyc(R) NDA 2Celsis Outlines the Top Five Advantages of Cryo-plateable Hepatocytes 2Celsis Outlines the Top Five Advantages of Cryo-plateable Hepatocytes 3Celsis Outlines the Top Five Advantages of Cryo-plateable Hepatocytes 4
(Date:6/16/2015)... Fingerprint Cards (FPC) raises the revenue guidance for ... at least 340 MSEK to that it will amount to ... growth and orders received the revenue guidance for 2015 is ... will exceed 1,500 MSEK to an updated guidance that revenue ... Due to receipt of orders of touch fingerprint sensors with ...
(Date:6/12/2015)... , June 12, 2015  Securus Technologies, ... technology solutions for public safety, investigation, corrections and ... its patent to electronically capture, analyze and identify ... facial recognition methods. This system can: ... by an enrollment and subsequent sign-on process is ...
(Date:6/9/2015)... 09, 2015 Research and Markets  ( ... "Gesture Recognition & Touchless Sensing Market by ... & Others), Product (Biometric & Sanitary Equipment) & ... report to their offering. The total ... to reach $ 23.55 Billion by 2020 at ...
Breaking Biology News(10 mins):Fingerprint Cards Raises the Revenue Guidance for Q2 2015 and for the Full Year 2015 2Fingerprint Cards Raises the Revenue Guidance for Q2 2015 and for the Full Year 2015 3Securus Announces Patent Issued for Authorized Presence Verification During Video Visitation 2Global Gesture Recognition & Touchless Sensing (Technology, Application & Products) Market 2015-2020 2
... forest cover in the eastern United States in recent decades ... analysis published in the April 2010 issue of BioScience ... A. Drummond and Thomas R. Loveland of the US Geological ... were cleared for agriculture on a large scale, but from ...
... Four billion years ago, our then stripling sun radiated only 70 ... things on Earth being equal, with so little energy reaching the ... But ancient rocks hold ample evidence that the early Earth was ... something must have compensated for the reduced solar output and kept ...
... DURHAM, N.C. The number of sea turtles inadvertently ... years may reach into the millions, according to the ... from gillnet, trawl and longline fisheries worldwide. The ... journal Conservation Letters , analyzed data compiled ...
Cached Biology News:Early Earth absorbed more sunlight -- no extreme greenhouse needed to keep water wet 2Early Earth absorbed more sunlight -- no extreme greenhouse needed to keep water wet 3Early Earth absorbed more sunlight -- no extreme greenhouse needed to keep water wet 4Commercial fishing estimated to kill millions of sea turtles 2Commercial fishing estimated to kill millions of sea turtles 3
Mouse monoclonal antibody raised against a partial recombinant ACTN4. NCBI Entrez Gene ID = ACTN4...
Rabbit polyclonal antibody to GluR2...
... can be used to test the crossreactivity ... sera that are commonly used as blocking ... spots for 19 different protein preparations on ... crossreactivity and species specificity, QC of purified ...
... array sample elements. , ,Includes: , DiscoverLight ... BSA in PBS (10X): 50 ml , ... , BupH Phosphate Buffered Saline: 8 packs ... ml ampules , SuperSignal West Pico Luminol Enhancer: 2 ...
Biology Products: